| abstract |
The invention discloses a nucleotide-protein complex dCas-HDAC1/gRNA KRAS containing a targeted mutant KRAS fusion gene, first catalyzing death Cas9 as a DNA binding device, and then fused with transcription inhibitor histone deacetylase 1 (HDAC1) At the same time, this application designed a group of three crRNAs, covering the 1500bp range of the KRAS promoter, and identified crRNA1, crRNA2 and crRNA3 to effectively silence KRAS, the inhibition of KRAS can significantly inhibit cell growth, inhibit soft agar Colony formation in KRAS-mutated cancer cells can be induced. |